Ciba-Geigy
Executive Summary
Signs agreement with privately-held Tanox Biosystems for joint development of monoclonal antibody-based products to treat allergic reactions mediated by immunoglobulin E. Ciba-Geigy will pursue clinical development of anti-IgE monoclonal antibodies designed by Tanox. In return, Houston-based Tanox will receive financial payments and share manufacturing and promotion rights to resulting products.